B-type natriuretic peptide prohormone (NT-proBNP): The BEAt-DKD consortium, which assessed biomarkers to predict the rate of estimated GFR reduction in the early stages of CKD in patients with DM, showed that NT-proBNP predicts reduction of estimated GFR (88). This evidence concerns the gene NPPB and chronic kidney disease.